Sana Biotechnology, Inc. (SANA) Bundle
A Brief History of Sana Biotechnology, Inc. (SANA)
Foundation and Early Years
Sana Biotechnology, Inc. was founded in 2018, emerging from a vision to harness the power of cell and gene therapies to treat diseases. The company is headquartered in Seattle, Washington.
Funding Rounds
In its early stages, Sana raised significant capital through various funding rounds:
- Series A: $100 million in July 2018
- Series B: $108 million in September 2019
- Series C: $150 million in October 2020
- IPO: $1.3 billion on February 2021
Technological Developments
Sana focuses on engineering cells to create medicines that can transform patients' lives. The key technologies include:
- Gene editing
- Cell engineering
- Therapeutic and preventive gene therapies
Clinical Trials and Partnerships
As of September 2023, Sana has initiated several clinical trials. Notable partnerships include collaborations with:
- University of Washington
- Massachusetts Institute of Technology (MIT)
- Broad Institute
Financial Performance
The financial performance of Sana Biotechnology has demonstrated significant growth:
| Year | Revenue (in millions) | Net Income (in millions) | Market Capitalization (as of September 2023, in billions) |
|---|---|---|---|
| 2020 | $0.0 | ($90.6) | $1.4 |
| 2021 | $0.0 | ($137.5) | $2.1 |
| 2022 | $12.3 | ($150.3) | $1.5 |
| 2023 (Projected) | $35.0 | ($120.0) | $2.0 |
Recent Developments
Sana Biotechnology has made advancements in its pipeline, focusing on therapies for:
- Neurological diseases
- Oncology
- Genetic disorders
Employee Growth
Since its inception, Sana has expanded its workforce significantly:
| Year | Number of Employees |
|---|---|
| 2018 | 25 |
| 2019 | 50 |
| 2020 | 100 |
| 2021 | 200 |
| 2023 | 300 |
Stock Performance
As of September 2023, the stock performance of Sana Biotechnology, Inc. shows:
| Date | Stock Price (in USD) | Market Cap (in billions) |
|---|---|---|
| February 2021 (IPO) | $20.00 | $1.3 |
| September 2021 | $25.00 | $1.8 |
| September 2022 | $15.00 | $1.0 |
| September 2023 | $18.00 | $2.0 |
Future Outlook
Sana Biotechnology has outlined its vision for the future, projecting:
- Continued growth in clinical trials
- Expansion of partnerships
- Increased investment in research and development
A Who Owns Sana Biotechnology, Inc. (SANA)
Company Overview
Company Overview
Sana Biotechnology, Inc. (SANA) is a clinical-stage biotechnology company focused on the development of engineered cell therapies. The company aims to create new medicines that repair or replace cells and tissues that have been damaged by disease or injury.
Major Shareholders
| Shareholder | Shares Owned | % of Total Shares |
|---|---|---|
| Vanguard Group, Inc. | 4,340,000 | 10.0% |
| BlackRock, Inc. | 4,000,000 | 9.2% |
| FMR LLC (Fidelity) | 3,500,000 | 8.0% |
| State Street Corporation | 3,200,000 | 7.4% |
| Perceptive Advisors LLC | 2,900,000 | 6.7% |
Institutional Ownership
As of the latest quarterly report, institutional investors own a significant portion of Sana Biotechnology's shares. This indicates a strong level of confidence from established financial entities.
| Institution | Shares Owned | % of Total Shares |
|---|---|---|
| Vanguard Group, Inc. | 4,340,000 | 10.0% |
| BlackRock, Inc. | 4,000,000 | 9.2% |
| FMR LLC (Fidelity) | 3,500,000 | 8.0% |
| State Street Corporation | 3,200,000 | 7.4% |
| Perceptive Advisors LLC | 2,900,000 | 6.7% |
Insider Ownership
Insiders of Sana Biotechnology maintain shares in the company, reflecting their commitment and belief in the company's future. The data regarding insider ownership is as follows:
| Insider Name | Position | Shares Owned | % of Total Shares |
|---|---|---|---|
| Steve Harr | CEO | 600,000 | 1.4% |
| Sharon Hrynkiewicz | CFO | 250,000 | 0.6% |
| Leah Rosenthal | COO | 300,000 | 0.7% |
Recent Stock Performance
The stock performance of Sana Biotechnology has witnessed various fluctuations over recent months.
| Date | Stock Price ($) | Market Cap ($) |
|---|---|---|
| October 2023 | 15.25 | 1.5 billion |
| September 2023 | 14.80 | 1.4 billion |
| August 2023 | 13.60 | 1.3 billion |
Financial Overview
As of the latest fiscal report, Sana Biotechnology's financial health shows the following metrics:
| Financial Metric | Amount ($) |
|---|---|
| Total Assets | 200 million |
| Total Liabilities | 50 million |
| Revenue (Last Quarter) | 10 million |
| Net Loss (Last Quarter) | 15 million |
Sana Biotechnology, Inc. (SANA) Mission Statement
Mission Overview
Sana Biotechnology, Inc. is a clinical-stage biotechnology company focused on leveraging its proprietary technology to create and deliver transformative cell and gene therapies. The company's mission emphasizes a commitment to translating scientific innovation into meaningful therapies for patients with serious diseases.
Core Values
- Innovation: Pioneering novel approaches in the field of biotechnology.
- Integrity: Upholding the highest standards of ethical practices.
- Collaboration: Fostering partnerships to enhance scientific endeavors.
- Patient-Centricity: Prioritizing the needs and well-being of patients in all endeavors.
Strategic Goals
Sana Biotechnology is dedicated to the following strategic objectives:
- Developing state-of-the-art cell and gene therapies.
- Expanding the therapeutic pipeline to address various unmet medical needs.
- Building robust partnerships and collaborations to enhance research and development.
- Ensuring regulatory compliance and maintaining high-quality standards in product development.
Recent Financial Performance
As of the latest financial report, Sana Biotechnology reported the following key financial metrics:
| Financial Metric | Q2 2023 | Year-to-Date 2023 |
|---|---|---|
| Total Revenue | $0 million | $0 million |
| Research and Development Expenses | $37.2 million | $76.9 million |
| General and Administrative Expenses | $8.9 million | $19.1 million |
| Net Loss | ($46.1 million) | ($96.0 million) |
| Cash, Cash Equivalents, and Marketable Securities | $185.0 million | $185.0 million |
| Total Assets | $196.4 million | $196.4 million |
Pipeline and Product Development
Sana Biotechnology has identified several key therapeutic areas for its research and development, including:
- Gene Editing
- Cell Therapy
- Oncology
- Metabolic Diseases
Partnerships and Collaborations
The company has formed various collaborations to enhance its research capabilities, including:
- Collaboration with the University of Washington on gene therapy technologies.
- Partnerships with notable biopharma firms for technology sharing and development.
Recent Developments
Key highlights of Sana Biotechnology's recent activities include:
- Management of clinical trials for its lead product candidates.
- Engagement in presentations at various biotechnology conferences.
- Continued investment in research facilities and technology advancement.
Future Outlook
The future outlook for Sana Biotechnology is tied to upcoming clinical trial results and the progression of its therapeutic candidates through regulatory pathways. The company remains optimistic about its ability to deliver innovative treatments aimed at improving patient outcomes.
How Sana Biotechnology, Inc. (SANA) Works
Business Model
Business Model
Sana Biotechnology, Inc. operates within the realm of biotechnology, focusing on gene therapies and cell engineering. The company aims to create transformative therapies for patients with a range of conditions.
The company’s strategy includes:
- Developing allogeneic cell therapies.
- Utilizing gene editing technologies.
- Fostering partnerships with academic institutions and other biotech firms.
Research and Development
As of Q3 2023, Sana has invested significantly in R&D. The company reported R&D expenses amounting to approximately $39 million in the first half of 2023.
Key programs include:
- SANA-301: A T cell therapy for cancer.
- SANA-401: An engineered cell therapy for genetic disorders.
Financial Performance
For the fiscal year ended December 31, 2022, Sana Biotechnology reported:
| Financial Metric | Amount (USD) |
|---|---|
| Revenue | $25 million |
| Net Loss | ($129 million) |
| Total Assets | $250 million |
| Cash and Cash Equivalents | $125 million |
In Q2 2023, the company's cash burn rate was approximately $15 million per quarter.
Market Position
Sana Biotechnology competes with various entities in the gene therapy space. As of 2023, the global gene therapy market is projected to reach $13.3 billion by 2026, growing at a CAGR of 29.1% from 2021 to 2026.
Collaboration and Partnerships
Sana has formed strategic collaborations with leading organizations, including:
- Partnership with the University of Washington for cell-derived therapies.
- Collaboration with Gilead Sciences for innovative therapies.
These partnerships are crucial for sharing resources, expertise, and funding.
Clinical Trials
As of October 2023, Sana has multiple clinical trials underway, with a total of 5 active trials focusing on:
- Oncology
- Metabolic disorders
- Autoimmune conditions
The company aims to advance several therapies into the clinic by 2025.
Future Outlook
Predictive models indicate that Sana Biotechnology could achieve a market cap of up to $1.5 billion by 2026, assuming continued advancement in their therapies and successful clinical trials.
How Sana Biotechnology, Inc. (SANA) Makes Money
Business Model Overview
Business Model Overview
Sana Biotechnology, Inc. (SANA) focuses on utilizing gene editing and cell therapy technologies to develop transformative medicines. The company's revenue generation is primarily through collaborations, research and development (R&D), and potential future product sales.
Collaboration Agreements
Sana engages in partnerships with pharmaceutical and biotechnology companies to accelerate its drug development pipeline. These collaborations often involve:
- Upfront payments
- Milestone payments
- Royalties on sales
Financial Performance
As of Q2 2023, Sana Biotechnology reported the following financial metrics:
| Metric | Amount (in USD) |
|---|---|
| Revenue | $0 |
| Net Loss | $(74) million |
| Research and Development Expenses | $63 million |
| General and Administrative Expenses | $11 million |
| Cash and Cash Equivalents | $375 million |
| Market Capitalization | $1.02 billion |
Product Development Pipeline
The company's focus is on developing therapies aimed at serious diseases through its innovative gene editing platforms. Key areas of pipeline development include:
- Cell therapies
- Gene therapies
- Regenerative medicine
As of September 2023, Sana has several candidates in clinical trials, which are important for future revenue generation through potential product launches and sales.
Potential Revenue Streams
Upon successful development and commercialization of their product candidates, Sana Biotechnology anticipates several revenue streams:
- Direct product sales
- Milestone payments from partners upon achieving developmental milestones
- Royalties from partnered products
The forecasted market for cell and gene therapies is projected to reach over $200 billion by 2025, creating substantial opportunity for revenue generation.
Market Position and Competitive Landscape
Sana operates within a highly competitive biotech landscape. Key competitors include:
- CRISPR Therapeutics
- Editas Medicine
- Intellia Therapeutics
Strategic collaborations and advancements in technology are critical for maintaining a competitive edge in this evolving market.
Investment and Funding
As of the latest data, Sana Biotechnology has raised approximately $500 million in funding since its inception through various funding rounds:
| Funding Round | Amount Raised (in USD) |
|---|---|
| Series A | $100 million |
| Series B | $200 million |
| IPO | $200 million |
Future Outlook
The ongoing investment in R&D, along with strategic partnerships, is crucial for Sana's ability to monetize its technologies effectively in the long term. The progression of its pipeline candidates into late-stage trials will significantly influence potential revenue generation and market share.
Sana Biotechnology, Inc. (SANA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support